Low-Grade Inflammation Modifies Cardiovascular Risk Even at Very Low LDL-C Levels
- 10 July 2018
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 138 (2) , 150-153
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsNew England Journal of Medicine, 2017
- Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention PopulationCirculation, 2016
- Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCirculation, 2015
- Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspectiveEuropean Heart Journal, 2015
- High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapyInternational Journal of Cardiology, 2013
- Myocardial infarction accelerates atherosclerosisNature, 2012
- Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary EventsEuropean Heart Journal, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Biomarkers of Atherosclerotic Plaque Instability and RuptureArteriosclerosis, Thrombosis, and Vascular Biology, 2007